Background The global burden of non-alcoholic fatty liver disease (NAFLD) parallels the
increase in obesity rates across the world. Although overweight and obesity status are …

Background The clinical presentation and outcomes of non-alcoholic fatty liver disease
(NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular …

Background & Aims Fibrosis is a key determinant of clinical outcomes in nonalcoholic fatty
liver disease (NAFLD), but time-dependent risk of mortality has not been reported in …

Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world's adult population
and is a major public health concern. NAFLD is defined by the presence of hepatic steatosis …

The incidence and prevalence of non‐alcoholic fatty liver disease (NAFLD) have been
steadily increasing worldwide, with a huge societal and economic burden. Recently, NAFLD …

Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver
transplantation (LT) in Western Countries, both for end stage liver disease and …

Cardiac diseases are one of the most common causes of morbidity and mortality following
liver transplantation (LT). Prior studies have shown that cardiac diseases affect close to one …

Background Non-alcoholic steatohepatitis (NASH) is the second-leading indication for liver
transplantation (LT) worldwide and is projected to become the leading indication. Our study …

Background Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver
disease globally. While the prevalence, impact, and causes of mortality have been …

Background and Aims Non-alcoholic steatohepatitis (NASH) cirrhosis is rapidly growing as
an indication for liver transplant (ation)(LT). However, the natural history of NASH cirrhosis …